HEADER APOPTOSIS REGULATOR/INHIBITOR 26-JUL-13 4LVT TITLE BCL_2-NAVITOCLAX (ABT-263) COMPLEX COMPND MOL_ID: 1; COMPND 2 MOLECULE: APOPTOSIS REGULATOR BCL-2; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: UNP RESIDUES 1-34, 92-207; COMPND 5 ENGINEERED: YES; COMPND 6 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: BCL2; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS 8 HELICES, APOPTOSIS REGULATOR-INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR C.H.PARK REVDAT 3 28-FEB-24 4LVT 1 REMARK SEQADV REVDAT 2 02-AUG-17 4LVT 1 SOURCE REMARK REVDAT 1 14-AUG-13 4LVT 0 JRNL AUTH A.J.SOUERS,J.D.LEVERSON,E.R.BOGHAERT,S.L.ACKLER,N.D.CATRON, JRNL AUTH 2 J.CHEN,B.D.DAYTON,H.DING,S.H.ENSCHEDE,W.J.FAIRBROTHER, JRNL AUTH 3 D.C.HUANG,S.G.HYMOWITZ,S.JIN,S.L.KHAW,P.J.KOVAR,L.T.LAM, JRNL AUTH 4 J.LEE,H.L.MAECKER,K.C.MARSH,K.D.MASON,M.J.MITTEN,P.M.NIMMER, JRNL AUTH 5 A.OLEKSIJEW,C.H.PARK,C.M.PARK,D.C.PHILLIPS,A.W.ROBERTS, JRNL AUTH 6 D.SAMPATH,J.F.SEYMOUR,M.L.SMITH,G.M.SULLIVAN,S.K.TAHIR, JRNL AUTH 7 C.TSE,M.D.WENDT,Y.XIAO,J.C.XUE,H.ZHANG,R.A.HUMERICKHOUSE, JRNL AUTH 8 S.H.ROSENBERG,S.W.ELMORE JRNL TITL ABT-199, A POTENT AND SELECTIVE BCL-2 INHIBITOR, ACHIEVES JRNL TITL 2 ANTITUMOR ACTIVITY WHILE SPARING PLATELETS. JRNL REF NAT.MED. (N.Y.) V. 19 202 2013 JRNL REFN ISSN 1078-8956 JRNL PMID 23291630 JRNL DOI 10.1038/NM.3048 REMARK 2 REMARK 2 RESOLUTION. 2.05 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER-TNT 2.5.1 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SMART,VONRHEIN,WOMACK, REMARK 3 : MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.05 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 28.92 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.6 REMARK 3 NUMBER OF REFLECTIONS : 19115 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.172 REMARK 3 R VALUE (WORKING SET) : 0.169 REMARK 3 FREE R VALUE : 0.222 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.150 REMARK 3 FREE R VALUE TEST SET COUNT : 984 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 9 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.05 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.17 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.55 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 3019 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.1761 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2864 REMARK 3 BIN R VALUE (WORKING SET) : 0.1733 REMARK 3 BIN FREE R VALUE : 0.2309 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.13 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 155 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2324 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 130 REMARK 3 SOLVENT ATOMS : 175 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 23.07 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 27.56 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -9.80522 REMARK 3 B22 (A**2) : 5.96173 REMARK 3 B33 (A**2) : 3.84349 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 1.95546 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : NULL REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : NULL REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : NULL REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : NULL REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : NULL REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : NULL REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : NULL ; NULL ; NULL REMARK 3 BOND ANGLES : NULL ; NULL ; NULL REMARK 3 TORSION ANGLES : NULL ; NULL ; NULL REMARK 3 TRIGONAL CARBON PLANES : NULL ; NULL ; NULL REMARK 3 GENERAL PLANES : NULL ; NULL ; NULL REMARK 3 ISOTROPIC THERMAL FACTORS : NULL ; NULL ; NULL REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : NULL ; NULL ; NULL REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : NULL ; NULL ; NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : NULL REMARK 3 BOND ANGLES (DEGREES) : NULL REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : NULL REMARK 3 OTHER TORSION ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4LVT COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 29-JUL-13. REMARK 100 THE DEPOSITION ID IS D_1000081148. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 04-DEC-08 REMARK 200 TEMPERATURE (KELVIN) : 110 REMARK 200 PH : 4.2 REMARK 200 NUMBER OF CRYSTALS USED : NULL REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-BM REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : MIRRORS REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 210 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 19115 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.050 REMARK 200 RESOLUTION RANGE LOW (A) : 65.120 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.6 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.05 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.17 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.6 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 38.13 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.99 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.5 M (NH4)2SO4, 0.1 M NA ACETATE, 0.2 REMARK 280 M NACL, PH 4.2, VAPOR DIFFUSION, TEMPERATURE 296K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 34.04000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A -1 REMARK 465 ALA A 0 REMARK 465 HIS A 1 REMARK 465 PRO A 2 REMARK 465 GLY A 3 REMARK 465 ARG A 4 REMARK 465 THR A 5 REMARK 465 GLY A 6 REMARK 465 GLY A 31 REMARK 465 ASP A 32 REMARK 465 ASP A 73 REMARK 465 VAL A 74 REMARK 465 GLU A 75 REMARK 465 GLU A 76 REMARK 465 ASN A 77 REMARK 465 ARG A 78 REMARK 465 THR A 79 REMARK 465 GLU A 80 REMARK 465 ALA A 81 REMARK 465 PRO A 82 REMARK 465 GLU A 83 REMARK 465 GLY A 84 REMARK 465 THR A 85 REMARK 465 GLU A 86 REMARK 465 SER A 202 REMARK 465 MET A 203 REMARK 465 ARG A 204 REMARK 465 MET B -1 REMARK 465 ALA B 0 REMARK 465 HIS B 1 REMARK 465 PRO B 2 REMARK 465 GLY B 3 REMARK 465 ARG B 4 REMARK 465 THR B 5 REMARK 465 GLY B 6 REMARK 465 GLY B 31 REMARK 465 ASP B 32 REMARK 465 ASP B 73 REMARK 465 VAL B 74 REMARK 465 GLU B 75 REMARK 465 GLU B 76 REMARK 465 ASN B 77 REMARK 465 ARG B 78 REMARK 465 THR B 79 REMARK 465 GLU B 80 REMARK 465 ALA B 81 REMARK 465 PRO B 82 REMARK 465 GLU B 83 REMARK 465 GLY B 84 REMARK 465 THR B 85 REMARK 465 GLU B 86 REMARK 465 SER B 202 REMARK 465 MET B 203 REMARK 465 ARG B 204 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 PRO A 201 C - N - CD ANGL. DEV. = -22.4 DEGREES REMARK 500 PRO B 201 C - N - CD ANGL. DEV. = -22.0 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 TYR A 105 53.28 -119.50 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 1XJ A 301 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 1XJ B 301 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 4LXD RELATED DB: PDB REMARK 900 RELATED ID: 4LXE RELATED DB: PDB DBREF 4LVT A -1 32 UNP P10415 BCL2_HUMAN 1 34 DBREF 4LVT A 89 204 UNP P10415 BCL2_HUMAN 92 207 DBREF 4LVT B -1 32 UNP P10415 BCL2_HUMAN 1 34 DBREF 4LVT B 89 204 UNP P10415 BCL2_HUMAN 92 207 SEQADV 4LVT PRO A 2 UNP P10415 ALA 4 ENGINEERED MUTATION SEQADV 4LVT ASP A 73 UNP P10415 LINKER SEQADV 4LVT VAL A 74 UNP P10415 LINKER SEQADV 4LVT GLU A 75 UNP P10415 LINKER SEQADV 4LVT GLU A 76 UNP P10415 LINKER SEQADV 4LVT ASN A 77 UNP P10415 LINKER SEQADV 4LVT ARG A 78 UNP P10415 LINKER SEQADV 4LVT THR A 79 UNP P10415 LINKER SEQADV 4LVT GLU A 80 UNP P10415 LINKER SEQADV 4LVT ALA A 81 UNP P10415 LINKER SEQADV 4LVT PRO A 82 UNP P10415 LINKER SEQADV 4LVT GLU A 83 UNP P10415 LINKER SEQADV 4LVT GLY A 84 UNP P10415 LINKER SEQADV 4LVT THR A 85 UNP P10415 LINKER SEQADV 4LVT GLU A 86 UNP P10415 LINKER SEQADV 4LVT SER A 87 UNP P10415 LINKER SEQADV 4LVT GLU A 88 UNP P10415 LINKER SEQADV 4LVT PRO B 2 UNP P10415 ALA 4 ENGINEERED MUTATION SEQADV 4LVT ASP B 73 UNP P10415 LINKER SEQADV 4LVT VAL B 74 UNP P10415 LINKER SEQADV 4LVT GLU B 75 UNP P10415 LINKER SEQADV 4LVT GLU B 76 UNP P10415 LINKER SEQADV 4LVT ASN B 77 UNP P10415 LINKER SEQADV 4LVT ARG B 78 UNP P10415 LINKER SEQADV 4LVT THR B 79 UNP P10415 LINKER SEQADV 4LVT GLU B 80 UNP P10415 LINKER SEQADV 4LVT ALA B 81 UNP P10415 LINKER SEQADV 4LVT PRO B 82 UNP P10415 LINKER SEQADV 4LVT GLU B 83 UNP P10415 LINKER SEQADV 4LVT GLY B 84 UNP P10415 LINKER SEQADV 4LVT THR B 85 UNP P10415 LINKER SEQADV 4LVT GLU B 86 UNP P10415 LINKER SEQADV 4LVT SER B 87 UNP P10415 LINKER SEQADV 4LVT GLU B 88 UNP P10415 LINKER SEQRES 1 A 166 MET ALA HIS PRO GLY ARG THR GLY TYR ASP ASN ARG GLU SEQRES 2 A 166 ILE VAL MET LYS TYR ILE HIS TYR LYS LEU SER GLN ARG SEQRES 3 A 166 GLY TYR GLU TRP ASP ALA GLY ASP ASP VAL GLU GLU ASN SEQRES 4 A 166 ARG THR GLU ALA PRO GLU GLY THR GLU SER GLU VAL VAL SEQRES 5 A 166 HIS LEU THR LEU ARG GLN ALA GLY ASP ASP PHE SER ARG SEQRES 6 A 166 ARG TYR ARG ARG ASP PHE ALA GLU MET SER SER GLN LEU SEQRES 7 A 166 HIS LEU THR PRO PHE THR ALA ARG GLY ARG PHE ALA THR SEQRES 8 A 166 VAL VAL GLU GLU LEU PHE ARG ASP GLY VAL ASN TRP GLY SEQRES 9 A 166 ARG ILE VAL ALA PHE PHE GLU PHE GLY GLY VAL MET CYS SEQRES 10 A 166 VAL GLU SER VAL ASN ARG GLU MET SER PRO LEU VAL ASP SEQRES 11 A 166 ASN ILE ALA LEU TRP MET THR GLU TYR LEU ASN ARG HIS SEQRES 12 A 166 LEU HIS THR TRP ILE GLN ASP ASN GLY GLY TRP ASP ALA SEQRES 13 A 166 PHE VAL GLU LEU TYR GLY PRO SER MET ARG SEQRES 1 B 166 MET ALA HIS PRO GLY ARG THR GLY TYR ASP ASN ARG GLU SEQRES 2 B 166 ILE VAL MET LYS TYR ILE HIS TYR LYS LEU SER GLN ARG SEQRES 3 B 166 GLY TYR GLU TRP ASP ALA GLY ASP ASP VAL GLU GLU ASN SEQRES 4 B 166 ARG THR GLU ALA PRO GLU GLY THR GLU SER GLU VAL VAL SEQRES 5 B 166 HIS LEU THR LEU ARG GLN ALA GLY ASP ASP PHE SER ARG SEQRES 6 B 166 ARG TYR ARG ARG ASP PHE ALA GLU MET SER SER GLN LEU SEQRES 7 B 166 HIS LEU THR PRO PHE THR ALA ARG GLY ARG PHE ALA THR SEQRES 8 B 166 VAL VAL GLU GLU LEU PHE ARG ASP GLY VAL ASN TRP GLY SEQRES 9 B 166 ARG ILE VAL ALA PHE PHE GLU PHE GLY GLY VAL MET CYS SEQRES 10 B 166 VAL GLU SER VAL ASN ARG GLU MET SER PRO LEU VAL ASP SEQRES 11 B 166 ASN ILE ALA LEU TRP MET THR GLU TYR LEU ASN ARG HIS SEQRES 12 B 166 LEU HIS THR TRP ILE GLN ASP ASN GLY GLY TRP ASP ALA SEQRES 13 B 166 PHE VAL GLU LEU TYR GLY PRO SER MET ARG HET 1XJ A 301 65 HET 1XJ B 301 65 HETNAM 1XJ 4-(4-{[2-(4-CHLOROPHENYL)-5,5-DIMETHYLCYCLOHEX-1-EN-1- HETNAM 2 1XJ YL]METHYL}PIPERAZIN-1-YL)-N-[(4-{[(2R)-4-(MORPHOLIN-4- HETNAM 3 1XJ YL)-1-(PHENYLSULFANYL)BUTAN-2-YL]AMINO}-3- HETNAM 4 1XJ [(TRIFLUOROMETHYL)SULFONYL]PHENYL)SULFONYL]BENZAMIDE FORMUL 3 1XJ 2(C47 H55 CL F3 N5 O6 S3) FORMUL 5 HOH *175(H2 O) HELIX 1 1 ASP A 8 GLN A 23 1 16 HELIX 2 2 GLU A 88 TYR A 105 1 18 HELIX 3 3 TYR A 105 GLN A 115 1 11 HELIX 4 4 THR A 122 PHE A 135 1 14 HELIX 5 5 ASN A 140 ARG A 161 1 22 HELIX 6 6 PRO A 165 LEU A 182 1 18 HELIX 7 7 LEU A 182 ASN A 189 1 8 HELIX 8 8 GLY A 191 GLY A 200 1 10 HELIX 9 9 ASP B 8 GLN B 23 1 16 HELIX 10 10 GLU B 88 TYR B 105 1 18 HELIX 11 11 TYR B 105 GLN B 115 1 11 HELIX 12 12 THR B 122 PHE B 135 1 14 HELIX 13 13 ASN B 140 ARG B 161 1 22 HELIX 14 14 PRO B 165 LEU B 182 1 18 HELIX 15 15 LEU B 182 ASN B 189 1 8 HELIX 16 16 GLY B 191 GLY B 200 1 10 CISPEP 1 GLY A 200 PRO A 201 0 6.16 CISPEP 2 GLY B 200 PRO B 201 0 6.68 SITE 1 AC1 19 ALA A 97 ASP A 100 PHE A 101 ARG A 104 SITE 2 AC1 19 TYR A 105 ASP A 108 PHE A 109 ASN A 140 SITE 3 AC1 19 TRP A 141 GLY A 142 ARG A 143 VAL A 145 SITE 4 AC1 19 ALA A 146 PHE A 195 LEU A 198 TYR A 199 SITE 5 AC1 19 HOH A 431 HOH A 434 HOH A 491 SITE 1 AC2 16 ALA B 97 ASP B 100 PHE B 101 TYR B 105 SITE 2 AC2 16 PHE B 109 VAL B 130 ASN B 140 TRP B 141 SITE 3 AC2 16 GLY B 142 VAL B 145 ALA B 146 VAL B 153 SITE 4 AC2 16 PHE B 195 LEU B 198 TYR B 199 HOH B 456 CRYST1 34.770 68.080 65.470 90.00 95.96 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.028760 0.000000 0.003003 0.00000 SCALE2 0.000000 0.014689 0.000000 0.00000 SCALE3 0.000000 0.000000 0.015357 0.00000